Introduction

A number of highly selective biologic therapies that target specific immunological pathways of psoriasis have emerged, including molecules that target interleukin (IL)-17. IL-17 has been identified as a key effector pathogenic cytokine in psoriasis, and validated as a highly effective therapeutic target for the treatment of plaque psoriasis.

Area covered

This review examines the therapeutic efficacy and safety of IL-17 inhibitors in plaque psoriasis and provides an overview of the efficacy and safety data of brodalumab compared with other IL-17 inhibitors.

Expert opinion

In the real world, the treatment of psoriasis has been revolutionized by the new class of drugs belonging to IL-17 inhibitors, with secukinumab, ixekizumab, and brodalumab currently licensed and approved for the treatment of moderate-to-severe plaque psoriasis. With its distinct mechanism of action, brodalumab may offer a unique advantage over other IL-17 inhibitors due to its rapid onset of action, achievement of complete skin clearance in a high proportion of patients, and its overall favorable safety profile. Importantly, treatment with systemic biologic drugs should be established early on in the course of the disease in order to prevent comorbidities and to allow patients to achieve a stable and persistent remission.

中文翻译：

---

Brodalumab在治疗慢性斑块状牛皮癣中的应用。

介绍

针对银屑病特定免疫途径的许多高度选择性的生物疗法已经出现，包括靶向白介素（IL）-17的分子。IL-17已被确定为牛皮癣的关键效应病原细胞因子，并已被证实是治疗斑块状牛皮癣的高效治疗靶标。

覆盖面积

这篇综述检查了IL-17抑制剂在斑块状牛皮癣中的治疗功效和安全性，并概述了与其他IL-17抑制剂相比，brodalumab的功效和安全性数据。

专家意见

在现实世界中，牛皮癣的治疗方法已被属于IL-17抑制剂的新型药物进行了革新，目前已授权并批准将secukinumab，ixekizumab和brodalumab用于治疗中度至重度斑块状牛皮癣。凭借其独特的作用机制，由于其快速起效，在高比例的患者中实现完全皮肤清除以及其总体有利的安全性，Brodalumab可能比其他IL-17抑制剂具有独特的优势。重要的是，应在疾病早期就建立全身性生物药物治疗，以预防合并症并让患者获得稳定和持久的缓解。